-ermin
Versions of the body's growth factor proteins.
- Drugs ending in -ermin: 29
- Approved somewhere: 7
- With a US drug page: 5
- Stem
- -ermin
- Class
- Versions of the body's growth factor proteins
Approved and clinical-stage drugs in ChEMBL whose names ending in -ermin or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Cenegermin | Approved | Neurotrophic tyrosine kinase receptor | Neurotrophic tyrosine kinase receptor agonist |
| Cimaglermin alfa | Phase 1 | — | — |
| Oremepermin alfa | Phase 1 | — | — |
| Telbermin | Phase 2 | FLT1, KDR | Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist |
| Nepidermin | Phase 3 | — | — |
| Palifermin | Approved | FGFR2 | Fibroblast growth factor receptor 2 agonist |
| Pegozafermin | Phase 3 | — | — |
| Trafermin | Phase 3 | FGFR2 | Fibroblast growth factor receptor 2 agonist |
| Aldafermin | Phase 2 | FGF1, KLB, FGFR4, KLB | FGF1/KLB activator |
| Pegbelfermin | Phase 2 | FGF1, KLB | FGF1/KLB agonist |
| Sprifermin | Phase 2 | — | — |
| Velafermin | Phase 2 | — | — |
| Efimosfermin alfa | Phase 1 | — | — |
| Efruxifermin | Phase 1 | — | — |
| Emfilermin | Phase 1 | — | — |
| Tasonermin | Approved | — | Unknown |
| Dulanermin | Phase 2 | TNFRSF10A, TNFRSF10B | TRAIL receptor-1 agonist |
| Pegipanermin | Phase 2 | — | — |
| Rilunermin alfa | Phase 2 | — | — |
| Efgivanermin alfa | Phase 1 | — | — |
| Eftozanermin alfa | Phase 1 | — | — |
| Dibotermin alfa | Approved | BMPR1A, ACVR2B, BMPR2, BMPR1B and 2 more | Bone morphogenetic protein receptor type-1A agonist |
| Eptotermin alfa | Approved | BMPR1A, BMPR2, BMPR1B, ACVR1 | Bone morphogenetic protein receptor type-1A agonist |
| Avotermin | Phase 3 | — | — |
| Radotermin | Phase 2 | — | — |
| Becaplermin | Approved | PDGFRA, PDGFRB | Platelet-derived growth factor receptor agonist |
| Mecasermin | Approved | IGF1R | Insulin-like growth factor I receptor agonist |
| Mecasermin rinfabate | Phase 2 | IGF1R | Insulin-like growth factor I receptor agonist |
| Liatermin | Phase 1 | GFRA1 | GDNF family receptor alpha-1 agonist |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO